Acne Fulminans: Severe Systemic Acne Emergency with Explosive Onset and Ulceration

Clinical Overview

Acne fulminans is a rare, severe acne variant with explosive sudden onset of painful, suppurative nodules, ulcerations, and systemic manifestations including fever, arthralgia, and constitutional symptoms. This dermatologic emergency requires immediate hospitalization and aggressive intervention with systemic corticosteroids and isotretinoin. Acne fulminans represents one of the most severe forms of acne vulgaris, with high risk of permanent severe scarring if not managed urgently. The condition primarily affects adolescent males (90% male predominance), with peak incidence 13-25 years. Despite rarity (0.1-0.4% of acne cases), acne fulminans requires recognition and rapid treatment due to medical and dermatologic urgency.

Epidemiology

Acne fulminans is rare, affecting 0.1-0.4% of acne patients, with striking male predominance (8-10:1 male to female). Peak age is 15-25 years, though can occur in young adults to age 35. Geographic variation is minimal. Strong association with testosterone-driven diseases: identical twin concordance is high, suggesting genetic predisposition. Familial severe acne history is present in 60-70% of cases. Systemic manifestations (fever, arthralgia) occur in 50-60% of patients, meeting criteria for "acne fulminans syndrome." Association with HLA-B12 and HLA-B44 alleles suggests immune-mediated component. Triggered by isotretinoin initiation in 10-20% of cases (isotretinoin-induced acne fulminans), though more commonly appears de novo in adolescents.

Pathophysiology

Acne fulminans results from severe dysregulation of innate and adaptive immunity combined with profound sebaceous gland hyperplasia: (1) Th1-mediated hypersensitivity reaction to Cutibacterium acnes antigens with excessive TNF-α and IL-6 production; (2) polymicrobial infection with C. acnes, S. aureus, and gram-negative organisms in necrotic tissue; (3) extreme sebaceous gland enlargement and sebum overproduction from androgen excess; (4) follicular rupture with rupture of nodules and cysts into dermis and subcutis; (5) excessive neutrophilic infiltration creating abscesses and necrotizing inflammation; (6) defective IL-10 and TGF-β production (anti-inflammatory mediators) perpetuating pro-inflammatory state. HLA associations suggest genetic predisposition to aberrant immune response. Elevated serum C3a and C5a indicate classical complement pathway activation from immune complex deposition.

Clinical Presentation

Acne fulminans presents with explosive sudden onset over days to weeks of severe nodular/cystic acne with striking systemic manifestations. Skin features: large, painful nodules (1-5 cm) and ulcerations with purulent drainage, hemorrhagic crusts, and extensive scarring. Distribution predominantly over chest, back, shoulders, and face. Lesions evolve rapidly from papules to nodules to ulcerations over 1-2 weeks. Secondary features: fever (38-40°C in 50-60%), arthralgia particularly knees and hips (40-50%), constitutional symptoms (malaise, weight loss), and myalgia. Laboratory abnormalities: elevated inflammatory markers (CRP 5-10 fold elevated, ESR markedly elevated), elevated WBC with left shift, elevated transaminases (30-40% of cases). Joint inflammation can be severe and debilitating. Psychological impact is extreme due to rapid disfigurement and systemic illness.

Diagnosis

Clinical diagnosis is based on characteristic explosive onset of severe suppurative nodular acne with systemic manifestations. Biopsy shows marked dermal and subcutaneous inflammation with neutrophilic abscesses, follicular rupture with foreign body giant cells responding to follicular contents, and granulomatous inflammation. Cultures of drainage fluid often show mixed flora (C. acnes, S. aureus, gram-negatives). Serology: HLA-B12 and HLA-B44 (present in 60-70% of cases), supporting immune-mediated pathogenesis. Imaging: chest X-ray is appropriate to rule out pulmonary involvement if systemic symptoms. Joint involvement may warrant rheumatology evaluation. Differential diagnosis: severe acne vulgaris (lacks systemic symptoms and explosive onset), acne conglobata (slower progression, less systemic involvement), and acne rosacea (different distribution, age group, and morphology).

Treatment Algorithm

Hospitalization: Most patients require hospitalization for initial management, IV antibiotic therapy, and close monitoring. Not all cases require hospitalization if systemic symptoms are mild, but severe or widespread disease warrants inpatient care.

Systemic Corticosteroids: First-line systemic therapy to suppress overwhelming inflammatory response. Prednisone 0.5-1 mg/kg/day (40-80 mg/day) for 4-6 weeks, then gradual taper over 8-12 weeks. Methylprednisolone 500-1000 mg IV daily for 3-5 days followed by oral prednisone can be used in severe cases. Achieves symptomatic improvement in 1-2 weeks and acne improvement over 4-6 weeks. Side effects are significant but necessary given disease severity.

Systemic Antibiotics: IV antibiotics for 2-4 weeks covering C. acnes and S. aureus. Cefazolin or cephalexin 1-2 g IV four times daily, or clindamycin 600 mg IV three times daily. Oral continuation (doxycycline 100 mg twice daily, minocycline 100 mg daily) for 4-6 additional weeks. Gram-negative coverage (ciprofloxacin 500 mg twice daily orally) if indicated by culture results. Total antibiotic course 8-10 weeks.

Isotretinoin: Essential therapy for long-term control and prevention of recurrence. Started after acute inflammation subsides (typically 4-6 weeks into corticosteroid therapy). Standard dosing: 0.5-1 mg/kg/day targeting cumulative dose of 120-150 mg/kg. Caution: isotretinoin initiation can paradoxically trigger acne flare in 10-20% of cases (isotretinoin-induced acne fulminans), managed by starting low-dose prednisone (20-30 mg/day) concurrently with isotretinoin and tapering over 4-6 weeks. iPLEDGE program mandatory with monthly monitoring.

Supportive Care: Drainage of accessible abscesses for symptomatic relief. Careful wound care with antibacterial cleansing. Pain management with non-narcotic or mild narcotic analgesics as needed. Nutritional support if significant constitutional symptoms. Psychological support given severe psychological impact from rapid disfigurement.

Prognosis

Acne fulminans without treatment is progressive with severe morbidity: persistent fever, constitutional symptoms worsening over weeks, and progressive scarring. With aggressive systemic corticosteroid and antibiotic therapy: 70-80% show marked improvement in systemic symptoms within 1-2 weeks, with 80-90% achieving significant acne control over 4-6 weeks. Isotretinoin therapy results in 85-90% complete remission or major improvement with <10% recurrence rate over 5 years. Residual scarring is permanent in 60-80% of cases despite optimal treatment, due to depth of inflammation before treatment. Dermatologic procedures (laser, subcision, microdermabrasion) after disease control can improve scar appearance in 60-70% of cases. Systemic manifestations (fever, arthralgia) resolve with corticosteroid therapy, typically within 2-4 weeks.

When to See a Dermatologist

Acne fulminans is a dermatologic emergency requiring urgent specialist evaluation. Any patient with sudden onset of severe suppurative acne with systemic symptoms (fever, joint pain) should be evaluated emergently by dermatology. Hospitalization is often appropriate for initial management. Coordinate with internal medicine or rheumatology for systemic manifestations.

Frequently Asked Questions

Q: Why did my acne suddenly become so severe?
A: Acne fulminans is a severe immune-mediated form of acne with genetic predisposition. It's not caused by anything you did—it's a disease process triggered by genetic and immune factors. The sudden onset and severity require immediate medical treatment.

Q: Will I have permanent scars?
A: Unfortunately, most patients with acne fulminans develop some permanent scarring due to the depth of inflammation. However, early aggressive treatment minimizes scarring, and dermatologic procedures after disease control can improve scar appearance significantly. Starting treatment immediately is crucial to minimize permanent damage.

Q: How long will treatment take?
A: Acute symptoms (fever, pain, systemic manifestations) typically improve within 2-4 weeks with corticosteroid therapy. Acne control takes 4-6 weeks with systemic corticosteroids and antibiotics. Isotretinoin treatment requires 4-6 months at full doses. Complete healing and improvement of scars can take many months to years.

Q: Can acne fulminans come back?
A: With proper isotretinoin therapy to cumulative doses of 120-150 mg/kg, recurrence is rare (<10% over 5 years). Without isotretinoin, recurrence is much more likely. Completing full isotretinoin therapy is critical to prevent relapse.

References